readthroughSign in
CompanyTRVINasdaqNew Haven, CT

Trevi Therapeutics

Trevi Therapeutics develops Haduvio, an oral nalbuphine extended-release therapy for chronic cough in idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough.

SCHEDULE 13G/ANov 16Latest SEC filing
Nov 9Latest story

November 2026

August 2026